Get started
Author

B Dietz

Observed name: B. Dietz
Institution: AbbVie (Germany)
OpenAlex ID: A5113590730
Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective
2007 · T. Mittendorf, B. Dietz, et al. · Lara D. Veeken · 37
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011
2012 · K. N. Simpson, R. W. Baran, et al. · Journal of Medical Economics · 7
Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument
2013 · S. L. Szeinbach, R. W. Baran, et al. · Alimentary Pharmacology & Therapeutics · 6
Par20 Effects of Long-term Adalimumab Therapy on Health Utility and Fatigue in Patients With Longstanding, Severe Rheumatoid Arthritis (ra)—results From a 3-year Follow-up Study
2005 · T Mittendorf, R Sterz, et al. · Value in Health · 2
Par3 Variation in Resource Utilization and Treatment Costs for Rheumatoid Arthritis (ra) Across 5 Countries in an Adalimumab (d2e7) Clinical Trial
2002 · L Van de Putte, R Bergemann, et al. · Value in Health · 2
PDF
Cost of switching darunavir+ritonavir (DRV+RTV) to lopinavir/ritonavir (LPV/r) in HIV‐1‐infected treatment‐naïve women of child‐bearing age (WOCBA)
2012 · R Baran, J Moller, et al. · Journal of the International AIDS Society · 1
PDF
Cost-effectiveness and budget impact of lopinavir/ritonavir and atazanavir plus ritonavir regimens based on 48-week results from the CASTLE study
2008 · KN Simpson, R Rajagopalan, et al. · Journal of the International AIDS Society · 1
PDF
Economic modeling of the combined effects of HIV disease, heart disease and lipoatrophy based on ACTG 5142 trial data
2008 · KN Simpson, R Rajagopalan, et al. · Journal of the International AIDS Society · 1
PDF
Cost-effectiveness of switching to second-line therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda
2008 · KN Simpson, B Dietz, et al. · Journal of the International AIDS Society · 1
PDF
Par19 Criteria-based Interpretation of Sf-36 Improvements From Adalimumab Plus Methotrexate (mtx) Combination Therapy Vs. Mtx Alone in Early Rheumatoid Arthritis (ra)
2005 · M Cifaldi, R Sterz, et al. · Value in Health · 1
PDF
Ut6 Improvement in Health Utility Among Rheumatoid Arthritis (ra) Patients Treated With Adalimumab (d2e7), a Fully Human Anti-tnf Monoclonal Antibody
2002 · L van de Putte, R Boggs, et al. · Value in Health · 1
PDF
Health-Economic Evaluation of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Treatment of Chronic Genotype 1 Hcv Infection in Germany
2016 · G Sroczynski, A Conrads-Frank, et al. · Value in Health
Minimal Important Difference (MID) of Response to the Hepatitis-C Virus Patient Reported Outcomes (HCV-PRO) Instrument in a Trial of Pegylated Interferon/Ribavirin (pegIFN/RBV) and Direct-Acting-Antivirals (DAA)
2013 · R.W. Baran, R.T. Anderson, et al. · Value in Health
Validation and Psychometric Evaluation of the German-Translated Hepatitis C Virus Patient Reported Outcomes (HCV-PRO) Health and Wellbeing Instrument in German HCV-Infected Patients Treated with Direct Acting Antivirals (DAAS) with or Without Ribavirin (RBV)
2013 · R.T. Anderson, R.W. Baran, et al. · Value in Health
Cost Minimization Comparison Of Darunavir + Ritonavir (DRV+RTV) To Lopinavir/Ritonavir (LPV/R) In HIV-1 Infected Treatment-Naïve Women Of Child Bearing Age (WOCBA)
2013 · K. Desai, J. Moller, et al. · Value in Health
PDF
PIN65 Cost-Effectiveness of First-Line Antiretroviral Regimens for Human Immunodeficiency Virus (HIV) in Colombia: An Analysis of Lopinavir/Ritonavir (LPV/R) and Darunavir Plus Ritonavir (DRV+RTV) in Treatment-Naïve Patients
2012 · J. Moller, K. Desai, et al. · Value in Health
880 Hepatitis C Virus Patient Reported Outcomes (hcvpro): Development and Validation of a Disease-specific Patient Reported Outcomes Instrument for Health-related Quality of Life Measurement
2012 · R.W. Baran, B. Dietz, et al. · Journal of Hepatology
PIN26 Economic and Health Related Quality of Life (HRQL) Comparison of Lopinavir/Ritonavir (LPV/R) and Atazanavir Plus Ritonavir (ATV+RTV)-Based Regimens for Antiretroviral (ARV) Experienced Brazilian Patients in 2011
2011 · K. Simpson, R. Baran, et al. · Value in Health
HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
2010 · RW Baran, B Dietz, et al. · Journal of the International AIDS Society
PDF
Pin54 Cost-effectiveness Analyses (cea) of Lopinavir/ritonavir (lpv/r) and Atazanavir Plus Ritonavir (atv + Rtv) Regimens for Antiretroviral (arv) Naïve Hiv-1 Infected Patients Based on Castle 48-week Study: Application to Sweden
2010 · K Simpson, R Baran, et al. · Value in Health
PDF
Pin37 Cost Effectiveness Analyses (cea) of Lopinavir/ritonavir (lpv/r) and Atazanavir Plus Ritonavir (atv + Rtv) Regimens Forantiretroviral(arv) Naïve Hiv-i Infected Patients Based on Castle 48-week Study: Application to Germany, Italy, Spain, and the United Kingdom
2010 · KN Simpson, B Dietz, et al. · Value in Health
Pin23 Poor Adherence to Treatment With Pegylated Interferon/ Ribavirin in Patients With Chronic Hepatitis C Infection Is Associated With Greater Health Care Costs
2009 · RW Baran, M Bhor, et al. · Value in Health
Pin33 Cost Effectiveness of Switching to Second Line Therapy With Lopinavir/ritonavir (lpv/r) in Kenya
2009 · KN Simpson, B Dietz, et al. · Value in Health
Par9 Effects of Adalimumab Monotherapy on Health Utility and Fatigue in Patients With Long-standing, Severe Rheumatoid Arthritis (ra)
2005 · T Mittendorf, R Sterz, et al. · Value in Health
PDF
Works count: 24
Citation count: 60
H-index: 3
I10-index: 1
Year
Topic
Type